Table 2. Adjusted HRs for Incident Fracture Comparing New Users of DOACs vs Warfarin Among Patients With Nonvalvular Atrial Fibrillation^a.

Outcomes by Prescribed DOAC	No. of Events		HR (95% CI)b	P Value
	DOAC Users	Matched Warfarin Users
Any DOACc
Hip fractures, first position	293	312	0.91 (0.78-1.07)	.27
Inpatient fractures, first position	697	791	0.87 (0.79-0.96)	.007
All fractures, first position	2685	2829	0.93 (0.88-0.98)	.009
Dabigatrand
Hip fractures, first position	182	186	0.98 (0.80-1.20)	.86
Inpatient fractures, first position	447	510	0.88 (0.78-1.00)	.06
All fractures, first position	1764	1803	0.96 (0.90-1.03)	.23
Rivaroxabane
Hip fractures, first position	128	170	0.89 (0.71-1.12)	.33
Inpatient fractures, first position	307	445	0.80 (0.69-0.93)	.003
All fractures, first position	1124	1493	0.82 (0.76-0.89)	<.001
Apixabanf
Hip fractures, first position	41	70	0.67 (0.45-0.98)	.04
Inpatient fractures, first position	92	174	0.60 (0.47-0.78)	<.001
All fractures, first position	396	521	0.86 (0.75-0.98)	.02

Abbreviations: DOAC, direct oral anticoagulant; HR, hazard ratio.

^aData are from the MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases from January 1, 2010, through September 30, 2015.

^bAdjusted for age, sex, CHA₂DS₂-VASc (congestive heart failure, hypertension, age [>65 years = 1 point; >75 years = 2 points], diabetes, and previous stroke/transient ischemic attack [2 points], vascular disease) score, high-dimensional propensity score, and frailty.

^cCompares 55 826 DOAC users and 55 826 warfarin users.

^dCompares 31 612 dabigatran users and 31 612 warfarin users.

^eCompares 32 440 rivaroxaban users and 32 440 warfarin users.

^fCompares 15 645 apixaban users and 15 645 warfarin users.